Inovio Pharmaceuticals, Inc. has entered into an underwriting agreement for a public offering of approximately 58.7 million shares of its common stock, aiming to raise around $80.5 million. This strategic move is significant for the company as it seeks to bolster its financial position and support ongoing operations.
The offering, priced at $1.05 per share, also includes pre-funded warrants allowing the purchase of an additional 12.7 million shares. Following the initial offering, the underwriters exercised an option to purchase an additional 10.7 million shares, further increasing the total expected proceeds.
Inovio, which operates in the pharmaceutical preparations sector, has stated that the net proceeds from this offering will be utilized to fund its operating expenses and capital requirements into late 2027. The company believes that the funding will enhance its ability to advance its clinical programs and support its business objectives.
Background
Inovio Pharmaceuticals, Inc. (CIK: 0001055726) is a Delaware-based company listed on the Nasdaq under the ticker symbol INO. The company is classified under the Standard Industrial Classification (SIC) 2834, which pertains to pharmaceutical preparations. Inovio has been involved in developing DNA-based therapies and vaccines to treat various diseases, including cancer and infectious diseases.
What the Filing Says
According to the recent SEC filing, dated November 9, 2026, Inovio entered into an underwriting agreement with Jefferies LLC and Piper Sandler & Co. The agreement outlines the issuance and sale of shares and warrants, with the offering expected to close on or about November 9, 2026, pending customary closing conditions. The filing states, "The net proceeds to the Company from the Offering... are expected to be approximately $80.5 million."
Impact
This offering may impact various stakeholders, including investors, competitors, and the broader pharmaceutical industry. Investors may view this as a positive step towards financial stability for Inovio, while competitors in the pharmaceutical preparations sector might need to evaluate their own capital strategies in light of Inovio's fundraising efforts.
What's Next
The offering is set to close soon, subject to the satisfaction of customary closing conditions. Further details regarding the use of proceeds and the company's operational plans may be disclosed in future filings.
Read Next
Alps Group Regains Compliance with Nasdaq Listing Standards
Ainos, Inc. Receives Nasdaq Delisting Notice Over Equity
Compass Therapeutics Receives Nasdaq Deficiency Notice
60 Degrees Pharmaceuticals Faces Nasdaq Delisting Risk
Biofrontera Inc. Faces Nasdaq Delisting Due to Low Stock Price
Senti Biosciences dismisses KPMG, appoints new auditor KNAV










